Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 9/20 | 0.44 |
| ▸ | AXL | P30530 | 1/20 | 0.42 |
| ▸ | MERTK | Q12866 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 3/20 | 0.40 |
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.39 |
| ▸ | MAP4K3 | Q8IVH8 | 2/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | CLK2 | P49760 | 1/20 | 0.36 |
| ▸ | CLK3 | P49761 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3718052 | 0.89 | MET (0.43) | METAXLMERTKEGFRGSK3B | |
| SCHEMBL3724980 | 0.86 | MET (0.42) | METAXLMERTKEGFRGSK3B | |
| SCHEMBL17287917 | 0.86 | MET (0.42) | METAXLMERTKEGFRGSK3B | |
| SCHEMBL3723366 | 0.85 | MET (0.49) | METMAP4K3JAK2FLT3 | |
| SCHEMBL3718389 | 0.85 | MAP4K3 (0.53) | METMAP4K3JAK2NTRK1FLT3 | |
| SCHEMBL3722828 | 0.80 | ACVR1B (0.46) | METDYRK1ACLK2 | |
| SCHEMBL3717439 | 0.76 | DRD2 (0.42) | — | |
| SCHEMBL3715497 | 0.76 | IRAK4 (0.48) | METMAP4K3NTRK1 | |
| SCHEMBL3722850 | 0.76 | ALK (0.45) | METJAK2MAP3K5 | |
| SCHEMBL3728093 | 0.75 | F12 (0.48) | MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2242742-B1 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2015-12-02 | — | — | EP | disclosed |
| US-8343966-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-01-01 | — | — | US | disclosed |
| EP-2242742-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2010-10-27 | — | — | EP | disclosed |
| US-20090215776-A1 | Organic compounds | ADCOCK CLAIRE | 2009-08-27 | — | — | US | disclosed |
| WO-2009087212-A2 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215776-A1 | Organic compounds | REN, RXFP1, MYLK | MET 1544/4885AXL 3452/4885MERTK 4434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.